GvHD immuno-predict

Barts is one of the largest haematological cancer centres in the UK and a major stem cell transplant centre, performing 50 allogeneic HSCT each year. Through our collaboration with Queen Mary University London/Barts Health NHS trust, we aim to develop, test and validate predictive GvHD biomarkers for use in the NHS.

Our primary aim is to leverage the combined strengths of expertise of QMUL/Barts Health in HSCT as a treatment for patients with blood cancer and Curenetics expertise in building AI algorithms for cancer response prediction to co-innovate and build a product that will reduce the incidence of GvHD, improve clinical outcomes of patients and save costs to the NHS. Beyond cost savings to the NHS, this product will be commercialised and made available to healthcare providers globally. If successful, it will serve as a companion risk assessment tool to be carried out before every transplant